单核细胞/高密度脂蛋白比值预测冠心病患者的长期临床结局：9 项研究的荟萃分析。

Monocyte to high-density lipoprotein ratio predict long-term clinical outcomes in patients with coronary heart disease: A meta-analysis of 9 studies.

机构信息

Department of Cardiology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen 518110, China.

Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China.

出版信息

Medicine (Baltimore). 2022 Aug 19;101(33):e30109. doi: 10.1097/MD.0000000000030109.

BACKGROUND

A novel inflammation-related biomarker, the monocyte to high-density lipoprotein cholesterol ratio (MHR), had a great relation to the development and prognosis of coronary atherosclerotic heart disease. Current study was to investigate whether the MHR was a potential tool in predicting the mortality and major adverse cardiac events (MACEs) in patients suffering coronary heart disease (CHD) by meta-analysis.

METHODS

The Cochrane Library, PubMed, MEDLINE, Scopus, EMBASE, and Web of science were searched for relevant cohort studies published prior to February 10, 2022. The association between MHR and mortality/MACEs was analyzed in patients with CHD. Hazard ratios (HR) with 95% confidence interval (CI) were calculated to estimate the strength of association.

RESULTS

In the meta-analysis, a total of 9 studies of 11,345 patients with CHD were included. Compared with the low level of MHR group, the high MHR value was associated with higher long-term MACEs (HR = 1.72 95% CI 1.36-2.18, P < .001), long-term mortality (HR = 1.71, 95% CI 1.10-2.66, P = .017), and in-hospital mortality/MACEs (HR = 2.82, 95% CI = 1.07-7.41, P = .036).

CONCLUSIONS

This study suggested that increased MHR value might be associated with higher long-term mortality and long-term MACEs in CHD patients. MHR might serve as a potential prognostic indicator for risk stratification in patients with CHD.

背景

一种新的炎症相关生物标志物——单核细胞与高密度脂蛋白胆固醇比值（MHR），与冠状动脉粥样硬化性心脏病的发生和预后有很大关系。本研究通过荟萃分析，旨在探讨 MHR 是否可作为预测冠心病患者死亡率和主要不良心脏事件（MACEs）的潜在工具。

方法

检索 Cochrane 图书馆、PubMed、MEDLINE、Scopus、EMBASE 和 Web of science 数据库，检索时间截至 2022 年 2 月 10 日，纳入有关 MHR 与冠心病患者死亡率/MACEs 相关性的队列研究。分析 MHR 与冠心病患者死亡率/MACEs 的关系。采用风险比（HR）及其 95%置信区间（CI）评估相关性强度。

结果

荟萃分析共纳入 9 项包含 11345 例冠心病患者的研究。与低 MHR 组相比，高 MHR 值与长期 MACEs（HR = 1.72，95% CI 1.36-2.18，P <.001）、长期死亡率（HR = 1.71，95% CI 1.10-2.66，P =.017）和住院期间死亡率/MACEs（HR = 2.82，95% CI = 1.07-7.41，P =.036）显著相关。